Wagner, A. J., Ravi, V., Ganjoo, K. N., Van Tine, B. A., Riedel, R. F., Chugh, R., … Dickson, M. A. (2019). ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 37). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Wagner, Andrew J., Vinod Ravi, Kristen N. Ganjoo, Brian Andrew Van Tine, Richard F. Riedel, Rashmi Chugh, Lee D. Cranmer, et al. “ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Wagner AJ, Ravi V, Ganjoo KN, Van Tine BA, Riedel RF, Chugh R, et al. ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.

Wagner, Andrew J., et al. “ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 37, no. 15, AMER SOC CLINICAL ONCOLOGY, 2019.

Wagner AJ, Ravi V, Ganjoo KN, Van Tine BA, Riedel RF, Chugh R, Cranmer LD, Gordon EM, Hornick JL, Kwiatkowski DJ, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Desai N, Dickson MA. ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.